Celcuity (CELC) Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
Go back to Celcuity (CELC) Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen| CEL Communications, Inc. (NASDAQ: CELC) | Delayed: 16.94 -0.3 (1.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.24 | 52 Week High | $0.00 | |||
| Open | $17.06 | 52 Week Low | $0.00 | |||
| Day High | $17.27 | P/E | N/A | |||
| Day Low | $16.91 | EPS | $0.00 | |||
| Volume | 90,283 | |||||
